MELLIS® VET

MELOXICAM

VETERINARY USE

Non-Steroidal Anti-Inflammatory Agent For Oral Use in Cats.

Formula

Each Mellis® Vet 0.2 mg tablet contains:
Meloxicam _____ 0,2 mg
Excipients q.s.p. _____ 70 mg

Technical Information

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID), a preferential cyclooxygenase-2 (COX2) inhibitor, belonging to the oxicam class. It inhibits the production of the prostaglandins involved in the inflammatory process. It has analgesic, anti-pyretic and anti-inflammatory properties. It is rapidly absorbed orally, achieves adequate plasma peak in up to 7 hours and can be administered with food, once daily. Meloxicam is eliminated in inactive form in feces, urine and bile.

Indications

Mellis® Vet 0.2 mg is indicated as an analgesic and anti-inflammatory agent for cats.

Dosage and how to use

Mellis® Vet 0.2 mg should only be administered orally. The recommended dose is 0.1 mg/kg at the first dose, followed by 0.05 mg/kg every 24 hours for up to 14 days, according to the table below:

Animal weight in kg	First day 0.1 mg/kg, once daily	Second day forward 0.05 mg/kg, once daily
2 kg	One 0.2 mg tablet	½ tablet of 0.2 mg
4 kg	Two 0.2 mg tablets	One 0.2 mg tablet

According to the efficacy study conducted in cats, Mellis® Vet 0.2 mg showed to be 100% effective for the relief of acute pain and inflammation, when administered at the initial dose of 0.1 mg/kg on the first day, followed by the 0.05 mg/kg dose on subsequent days, every 24 hours, for 7 days, in cats undergoing ovary-salpingo-hysterectomy (OSH). Treatment can be extended up to the 14th Day, according to the results obtained in the safety study conducted with the product.

Contraindications

The product should not be given to cats with hypersensitivity to meloxicam or any of the components of the formula. It is not recommended for pregnant, lactating female cats, and cats under 12 months of age, as no study was conducted in these groups. Mellis® Vet 0.2 mg, like all non-steroidal anti-inflammatory drugs, is not recommended for cats presenting bleeding disorders, cardiovascular diseases, hepatic, renal and gastrointestinal disorders, nor for dehydrated, hypovolemic and hypotensive animals.

Drug interactions

The concomitant use of Mellis® Vet 0.2 mg with anticoagulants, other steroidal or nonsteroidal anti-inflammatory drugs, diuretics, angiotensin-converting enzyme inhibitors (ACEI) and potentially nephrotoxic agents must be avoided due to the increased risk of adverse effects.

Adverse effects

Mellis® Vet 0.2 mg showed to be safe in a safety study conducted in cats, when administered at the recommended dose and at twice the recommended dose, for up to 14 consecutive days. Events of gastrointestinal irritation may occur, such as emesis (incidence of 10%) and bloody stools (incidence of 10%) and shortened activated partial thromboplastin time (aPTT). Adverse effects were transient and reversed with supportive treatment. During the 14-day period of treatment at the recommended dose and overdose, no changes were observed in hematological and biochemical tests (renal and hepatic profiles).

Gastrointestinal adverse effects, such as vomiting and bloody diarrhea are expected and frequently reported, especially with nonsteroidal anti-inflammatory drugs in overdose. At the recommended initial dose of 0.1 mg/kg and 0.05 mg/kg in subsequent doses, every 24 hours, some signs of gastrointestinal irritation can occur, such as emesis (incidence of 10%) and bloody stools (incidence of 10%), as well as shortened activated partial thromboplastin time (aPTT). Therefore, monitoring by a Veterinary doctor is advisable throughout treatment.

Precautions

The safety of Mellis® Vet 0.2 mg has not been investigated in pregnant or lactating female cats, in animals used for breeding, and those under 1 year of age.

Poisoning and overdose

In cases of poisoning or overdose, seek the advice of a Veterinary doctor for supportive treatment and physical and laboratory tests.

Mellis® Vet 0.2 mg, when used in overdose (twice the recommended dose) for 14 consecutive days, was considered safe. However, it caused signs of gastrointestinal irritation, such as emesis (incidence of 20%) and bloody stools (incidence of 20%) and shortened activated partial thromboplastin time (aPTT). Therefore, monitoring by a Veterinary doctor is recommended.

During the 14-day period of treatment at the recommended doses and in overdose, no changes were observed in hematological and biochemical tests (renal and hepatic profiles).

Warnings

Veterinary products must be kept out of the reach of children and pets. They should not be stored near food, drinks or personal hygiene products. No safety studies have been conducted in cats under 1 year of age, nor in pregnant and lactating female cats.

Presentation

Blister with 10 bisected tablets.

Blister with 4 bisected tablets (FREE SAMPLE).

Storage recommendations

Keep the product in a dry place, at room temperature (15oC to 30oC), away from direct sunlight and out of the reach of children and pets. In case of accidental ingestion, seek medical attention and take the product package with you. After splitting the tablet, the parts obtained must be used within 72 hours.

Lot, manufacturing and expiration date: see packaging.

SALE UNDER THE VETERINARIAN'S PRESCRIPTION AND APPLICATION.

Product registered with the Ministry of Agriculture, Livestock and Supply under no SP 001692-6 000007 on 4/28/2023.

Owner and manufacturer:
Biolab Sanus Farmacêutica Ltda.
Av. Francisco Samuel Lucchesi Filho, 1039, Bragança Paulista - SP
CEP: 12929-600 - CNPJ: 49.475.833/0018-46 - SAC: 0800 941 5566

Responsible technician: Daniela Ziolkowski, CRF-SP 29.486.

Expiry date: 24 months after the manufacturing date.

Avert